ES2051788T3 - Un producto farmaceutico. - Google Patents

Un producto farmaceutico.

Info

Publication number
ES2051788T3
ES2051788T3 ES88106401T ES88106401T ES2051788T3 ES 2051788 T3 ES2051788 T3 ES 2051788T3 ES 88106401 T ES88106401 T ES 88106401T ES 88106401 T ES88106401 T ES 88106401T ES 2051788 T3 ES2051788 T3 ES 2051788T3
Authority
ES
Spain
Prior art keywords
pharmaceutical product
improvement
inhibitors
dacarbazine
interferon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88106401T
Other languages
English (en)
Inventor
Sai P Sunkara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2051788T3 publication Critical patent/ES2051788T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A LA MEJORA DE LOS EFECTOS DE DEPLECION DE POLIAMINA, DE INHIBIDORES DE ORNITINA DESCARBOXILASA (ODC) SIENDO EFECTUADA LA MEJORA POR EL USO DE INTERFERON Y DACARBAZINA EN TERAPIA CONJUNTA CON DICHOS INHIBIDORES.
ES88106401T 1987-04-23 1988-04-21 Un producto farmaceutico. Expired - Lifetime ES2051788T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4189187A 1987-04-23 1987-04-23

Publications (1)

Publication Number Publication Date
ES2051788T3 true ES2051788T3 (es) 1994-07-01

Family

ID=21918900

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88106401T Expired - Lifetime ES2051788T3 (es) 1987-04-23 1988-04-21 Un producto farmaceutico.

Country Status (11)

Country Link
EP (1) EP0288055B1 (es)
JP (1) JPS63280019A (es)
KR (1) KR880012239A (es)
AT (1) ATE78174T1 (es)
AU (1) AU609120B2 (es)
DE (1) DE3872749T2 (es)
DK (1) DK167905B1 (es)
ES (1) ES2051788T3 (es)
GR (1) GR3005553T3 (es)
IE (1) IE61498B1 (es)
ZA (1) ZA882719B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0369944A1 (de) * 1988-11-18 1990-05-23 Ciba-Geigy Ag Substituierte Oxadiaminobutane
EP0452264A1 (de) * 1990-04-11 1991-10-16 Ciba-Geigy Ag Hydroxylamin-Verbindungen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499072A (en) * 1982-11-29 1985-02-12 Merrell Dow Pharmaceuticals Inc. Process for treating diseases with ODC inhibitors
US4999072A (en) * 1987-10-19 1991-03-12 Milliken Research Corporation Method of making an insole product

Also Published As

Publication number Publication date
DK222988A (da) 1988-10-24
IE61498B1 (en) 1994-11-02
JPS63280019A (ja) 1988-11-17
KR880012239A (ko) 1988-11-26
DK222988D0 (da) 1988-04-22
DE3872749D1 (de) 1992-08-20
DK167905B1 (da) 1994-01-03
GR3005553T3 (es) 1993-06-07
ATE78174T1 (de) 1992-08-15
IE881221L (en) 1988-10-23
ZA882719B (en) 1988-10-17
EP0288055B1 (en) 1992-07-15
EP0288055A1 (en) 1988-10-26
DE3872749T2 (de) 1992-12-03
AU1502388A (en) 1988-10-27
AU609120B2 (en) 1991-04-26

Similar Documents

Publication Publication Date Title
IL76932A (en) Synergistic pharmaceutical analgesic compositions containing dihydrocodeine and ibuprofen
ES2032382T3 (es) Metodo para preparar un medicamento para la prevencion o tratamiento de la endometriosis.
AU625830B2 (en) Transdermal delivery system
ZA928771B (en) Combination chemotherapy
IL84425A (en) (s) - (+) -ibuprofen-containing pharmaceutical compositions
ES2011120A6 (es) Forma de dosificacion para tratar las enfermedades cardiovasculares.
EP0325129A3 (en) Disubstituted pyridines
CA1265818C (en) NON-AROMATIC FLUOROALLYLAMINES MAO INHIBITORS
PH18061A (en) Anti-inflammatory and/or analgesic 2,3-diaryl-5-halo thiophenes
ZA923935B (en) New 2-amino-5-cyano-1,4-dihydropyridines,processes for their preparation and their use in medicaments
AU564439B2 (en) Pharmaceutical compositions containing l-alpha- glycerylphosphorylcholine
ES2051788T3 (es) Un producto farmaceutico.
ES8702142A1 (es) Procedimiento para preparar un medicamento a base de 2-amino-3-carboetoxiamino-6-(4-fluoro-bencilamino)-piridina y 4-acetamido-fenol
GR3001277T3 (en) Chlorpheniramine therapy
ES8404693A1 (es) Procedimiento de preparacion de nuevos amino-14 esteroides.
EP0273778A3 (en) Synergistic behavior of csf-1 and g-csf
FI851365L (fi) Liposomer med inhalerbara allergener foer behandling av allergener, foerfarande foer deras framstaellning och dessa innehaollande laekemedel.
ES8704903A1 (es) Un metodo para preparar 6-cloro-2-metil-1h-2,3,4,5-tetrahidro-3-benzazepen-n-oxido.
ES8300475A1 (es) Un procedimiento para la preparacion de un alergeno
AU1691888A (en) Compound active in cardiovascular therapy
GR3003773T3 (es)
JPS5758630A (en) Interferon inducer
ES8706441A1 (es) Procedimiento para preparar una composicion farmaceutica a base de sulpirida y un progestageno.
DE3680540D1 (de) Vorrichtung zur herstellung und zur verabreichung von getraenken.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 288055

Country of ref document: ES